Lakefront Biotherapeutics | GLPG - Pre Tax Profit


Lakefront Biotherapeutics reported EUR13.96M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
argenx SE USD 403.29M 17.24M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Biogen USD 377.7M 433.7M Mar/2026
Genmab DKK 55M 427M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
GRIFOLS EUR 190.51M 20.03M Jun/2025
Hikma Pharmaceutical USD 147.5M 3.5M Jun/2025
Incyte USD 343.6M 46.34M Mar/2026
Merck EUR 401M 886.1M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
UCB EUR 789M 427M Jun/2025
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026